Cellebrite DI (CLBT) Projected to Post Quarterly Earnings on Thursday

Cellebrite DI (NASDAQ:CLBT) is projected to announce its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of $0.0538 per share and revenue of $127.0140 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The company had revenue of $128.82 million for the quarter, compared to analysts’ expectations of $126.07 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. The business’s revenue for the quarter was up 28.8% compared to the same quarter last year. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $13.05 on Tuesday. Cellebrite DI has a 12 month low of $11.02 and a 12 month high of $20.45. The stock has a market cap of $3.26 billion, a price-to-earnings ratio of 42.10, a PEG ratio of 2.09 and a beta of 1.15. The stock’s 50 day moving average price is $13.62 and its 200 day moving average price is $15.67.

Analyst Ratings Changes

CLBT has been the topic of several research reports. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cellebrite DI presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Institutional Investors Weigh In On Cellebrite DI

A number of hedge funds have recently bought and sold shares of the company. ExodusPoint Capital Management LP raised its position in shares of Cellebrite DI by 121.0% during the fourth quarter. ExodusPoint Capital Management LP now owns 36,832 shares of the company’s stock valued at $664,000 after buying an additional 20,169 shares during the last quarter. Marex Group plc acquired a new position in shares of Cellebrite DI during the fourth quarter valued at about $602,000. Boothbay Fund Management LLC acquired a new position in shares of Cellebrite DI during the third quarter valued at about $386,000. First Trust Advisors LP acquired a new position in shares of Cellebrite DI during the second quarter valued at about $341,000. Finally, Armistice Capital LLC acquired a new position in shares of Cellebrite DI during the fourth quarter valued at about $302,000. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.